AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2020. The put-call ratio across all filers is 0.75 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24,084,510 | -45.1% | 2,338,302 | -12.2% | 1.68% | -53.7% |
Q2 2023 | $43,903,972 | +28.4% | 2,664,076 | -28.6% | 3.64% | -9.4% |
Q1 2023 | $34,192,246 | +27.9% | 3,732,778 | 0.0% | 4.02% | +43.7% |
Q4 2022 | $26,726,690 | +42.9% | 3,732,778 | 0.0% | 2.79% | +56.2% |
Q3 2022 | $18,701,000 | +105.3% | 3,732,778 | 0.0% | 1.79% | +103.3% |
Q2 2022 | $9,108,000 | -64.3% | 3,732,778 | 0.0% | 0.88% | -64.1% |
Q1 2022 | $25,495,000 | -15.5% | 3,732,778 | 0.0% | 2.45% | -10.3% |
Q4 2021 | $30,161,000 | +21.9% | 3,732,778 | +47.8% | 2.74% | +133.2% |
Q3 2021 | $24,749,000 | +47.4% | 2,525,452 | +1.2% | 1.17% | +33.8% |
Q2 2021 | $16,795,000 | -25.6% | 2,495,573 | 0.0% | 0.88% | -43.5% |
Q1 2021 | $22,560,000 | +78.5% | 2,495,573 | +31.9% | 1.55% | +37.4% |
Q4 2020 | $12,639,000 | +31.6% | 1,892,043 | -0.7% | 1.13% | -28.0% |
Q3 2020 | $9,606,000 | -37.7% | 1,905,990 | -0.1% | 1.57% | -38.8% |
Q2 2020 | $15,413,000 | +43.2% | 1,907,504 | +25.7% | 2.56% | +3.6% |
Q1 2020 | $10,767,000 | – | 1,517,296 | – | 2.47% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACUTA CAPITAL PARTNERS, LLC | 1,625,000 | $12,269,000 | 3.04% |
GENDELL JEFFREY L | 1,146,764 | $8,658,000 | 1.11% |
Broadfin Capital, LLC | 1,029,012 | $7,769,000 | 1.04% |
RTW INVESTMENTS, LP | 3,401,434 | $25,681,000 | 0.97% |
BRANDES INVESTMENT PARTNERS, LP | 3,651,948 | $27,571,000 | 0.66% |
Aristides Capital LLC | 71,520 | $540,000 | 0.42% |
Tekla Capital Management LLC | 814,588 | $6,150,000 | 0.23% |
INVESTORS ASSET MANAGEMENT OF GEORGIA INC /GA/ /ADV | 36,100 | $273,000 | 0.17% |
Leap Investments LP | 43,481 | $328,000 | 0.15% |
Brown Capital Management | 1,829,886 | $13,816,000 | 0.13% |